末梢動脈疾患（PAD）治療薬の世界市場（～2026年）

• 英文タイトル：Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04221 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は末梢動脈疾患（PAD）治療薬のグローバル市場について調査・分析したレポートです。種類別（抗血小板薬、二重抗血小板療法薬、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別末梢動脈疾患（PAD）治療薬の競争状況、市場シェア ・世界の末梢動脈疾患（PAD）治療薬市場：種類別市場規模 2015年-2020年（抗血小板薬、二重抗血小板療法薬、その他） ・世界の末梢動脈疾患（PAD）治療薬市場：種類別市場規模予測 2021年-2026年（抗血小板薬、二重抗血小板療法薬、その他） ・世界の末梢動脈疾患（PAD）治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の末梢動脈疾患（PAD）治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の末梢動脈疾患（PAD）治療薬市場分析：米国、カナダ ・ヨーロッパの末梢動脈疾患（PAD）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの末梢動脈疾患（PAD）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の末梢動脈疾患（PAD）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの末梢動脈疾患（PAD）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca Plc. (UK)、Bayer HealthCare Pharmaceuticals (Germany)、Bristol-Myers Squibb Company (US)、Merck & Co., Inc. (US)、Proteon Therapeutics, Inc. (US)、Sanofi S.A. (France)、Symic Bio, Inc. (US)、TheraVasc Inc. (US)、AnGes MG, Inc. (Japan)、Athersys, Inc. (US)、Betagenon AB (Sweden)、miRagen Therapeutics, Inc. (US)、Multi Gene Vascular Systems Ltd (Israel)、ViroMed Co. Ltd. (Korea) ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.

Market Analysis and Insights: Global Peripheral Arterial Disease (PAD) Therapeutics Market
The global Peripheral Arterial Disease (PAD) Therapeutics market size is projected to reach US$ 3109.7 million by 2026, from US$ 2940 million in 2020, at a CAGR of 5.3%% during 2021-2026.

Global Peripheral Arterial Disease (PAD) Therapeutics Scope and Market Size
Peripheral Arterial Disease (PAD) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Peripheral Arterial Disease (PAD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)

Market segment by Type, the product can be split into
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Anti-Platelet Drugs
1.4.3 Dual Antiplatelet Therapy Drugs
1.4.4 Others
1.5 Market by Application
1.5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2015-2026)
2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Regions
2.2.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Peripheral Arterial Disease (PAD) Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Peripheral Arterial Disease (PAD) Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Market Size
3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
3.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2019
3.3 Peripheral Arterial Disease (PAD) Therapeutics Key Players Head office and Area Served
3.4 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
3.5 Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)
5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
6.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in North America (2019-2020)
6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
6.4 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
7.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
7.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
8.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in China (2019-2020)
8.3 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
8.4 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
9.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
9.4 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
10.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
11.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in India (2019-2020)
11.3 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
11.4 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2015-2020)
12.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AstraZeneca Plc. (UK)
13.1.1 AstraZeneca Plc. (UK) Company Details
13.1.2 AstraZeneca Plc. (UK) Business Overview
13.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020))
13.1.5 AstraZeneca Plc. (UK) Recent Development
13.2 Bayer HealthCare Pharmaceuticals (Germany)
13.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Details
13.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
13.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
13.3 Bristol-Myers Squibb Company (US)
13.3.1 Bristol-Myers Squibb Company (US) Company Details
13.3.2 Bristol-Myers Squibb Company (US) Business Overview
13.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.3.5 Bristol-Myers Squibb Company (US) Recent Development
13.4 Merck & Co., Inc. (US)
13.4.1 Merck & Co., Inc. (US) Company Details
13.4.2 Merck & Co., Inc. (US) Business Overview
13.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.4.5 Merck & Co., Inc. (US) Recent Development
13.5 Proteon Therapeutics, Inc. (US)
13.5.1 Proteon Therapeutics, Inc. (US) Company Details
13.5.2 Proteon Therapeutics, Inc. (US) Business Overview
13.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.5.5 Proteon Therapeutics, Inc. (US) Recent Development
13.6 Sanofi S.A. (France)
13.6.1 Sanofi S.A. (France) Company Details
13.6.2 Sanofi S.A. (France) Business Overview
13.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.6.5 Sanofi S.A. (France) Recent Development
13.7 Symic Bio, Inc. (US)
13.7.1 Symic Bio, Inc. (US) Company Details
13.7.2 Symic Bio, Inc. (US) Business Overview
13.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.7.5 Symic Bio, Inc. (US) Recent Development
13.8 TheraVasc Inc. (US)
13.8.1 TheraVasc Inc. (US) Company Details
13.8.2 TheraVasc Inc. (US) Business Overview
13.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.8.5 TheraVasc Inc. (US) Recent Development
13.9 AnGes MG, Inc. (Japan)
13.9.1 AnGes MG, Inc. (Japan) Company Details
13.9.2 AnGes MG, Inc. (Japan) Business Overview
13.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.9.5 AnGes MG, Inc. (Japan) Recent Development
13.10 Athersys, Inc. (US)
13.10.1 Athersys, Inc. (US) Company Details
13.10.2 Athersys, Inc. (US) Business Overview
13.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
13.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
13.10.5 Athersys, Inc. (US) Recent Development
13.11 Betagenon AB (Sweden)
10.11.1 Betagenon AB (Sweden) Company Details
10.11.2 Betagenon AB (Sweden) Business Overview
10.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
10.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
10.11.5 Betagenon AB (Sweden) Recent Development
13.12 miRagen Therapeutics, Inc. (US)
10.12.1 miRagen Therapeutics, Inc. (US) Company Details
10.12.2 miRagen Therapeutics, Inc. (US) Business Overview
10.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
10.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
10.12.5 miRagen Therapeutics, Inc. (US) Recent Development
13.13 Multi Gene Vascular Systems Ltd (Israel)
10.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Details
10.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
10.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
10.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
10.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
13.14 ViroMed Co. Ltd. (Korea)
10.14.1 ViroMed Co. Ltd. (Korea) Company Details
10.14.2 ViroMed Co. Ltd. (Korea) Business Overview
10.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
10.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020)
10.14.5 ViroMed Co. Ltd. (Korea) Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Peripheral Arterial Disease (PAD) Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
Table 3. Ranking of Global Top Peripheral Arterial Disease (PAD) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Anti-Platelet Drugs
Table 6. Key Players of Dual Antiplatelet Therapy Drugs
Table 7. Key Players of Others
Table 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Peripheral Arterial Disease (PAD) Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Peripheral Arterial Disease (PAD) Therapeutics Players
Table 19. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2019)
Table 22. Global Peripheral Arterial Disease (PAD) Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
Table 25. Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Peripheral Arterial Disease (PAD) Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Peripheral Arterial Disease (PAD) Therapeutics Market Share (2019-2020)
Table 35. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2015-2020)
Table 37. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Peripheral Arterial Disease (PAD) Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Peripheral Arterial Disease (PAD) Therapeutics Market Share (2019-2020)
Table 41. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Peripheral Arterial Disease (PAD) Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Peripheral Arterial Disease (PAD) Therapeutics Market Share (2019-2020)
Table 47. China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2015-2020)
Table 49. China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Peripheral Arterial Disease (PAD) Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Peripheral Arterial Disease (PAD) Therapeutics Market Share (2019-2020)
Table 53. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Peripheral Arterial Disease (PAD) Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Peripheral Arterial Disease (PAD) Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Peripheral Arterial Disease (PAD) Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Peripheral Arterial Disease (PAD) Therapeutics Market Share (2019-2020)
Table 65. India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2015-2020)
Table 67. India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Peripheral Arterial Disease (PAD) Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Peripheral Arterial Disease (PAD) Therapeutics Market Share (2019-2020)
Table 71. Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2015-2020)
Table 75. AstraZeneca Plc. (UK) Company Details
Table 76. AstraZeneca Plc. (UK) Business Overview
Table 77. AstraZeneca Plc. (UK) Product
Table 78. AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 79. AstraZeneca Plc. (UK) Recent Development
Table 80. Bayer HealthCare Pharmaceuticals (Germany) Company Details
Table 81. Bayer HealthCare Pharmaceuticals (Germany) Business Overview
Table 82. Bayer HealthCare Pharmaceuticals (Germany) Product
Table 83. Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 84. Bayer HealthCare Pharmaceuticals (Germany) Recent Development
Table 85. Bristol-Myers Squibb Company (US) Company Details
Table 86. Bristol-Myers Squibb Company (US) Business Overview
Table 87. Bristol-Myers Squibb Company (US) Product
Table 88. Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 89. Bristol-Myers Squibb Company (US) Recent Development
Table 90. Merck & Co., Inc. (US) Company Details
Table 91. Merck & Co., Inc. (US) Business Overview
Table 92. Merck & Co., Inc. (US) Product
Table 93. Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 94. Merck & Co., Inc. (US) Recent Development
Table 95. Proteon Therapeutics, Inc. (US) Company Details
Table 96. Proteon Therapeutics, Inc. (US) Business Overview
Table 97. Proteon Therapeutics, Inc. (US) Product
Table 98. Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 99. Proteon Therapeutics, Inc. (US) Recent Development
Table 100. Sanofi S.A. (France) Company Details
Table 101. Sanofi S.A. (France) Business Overview
Table 102. Sanofi S.A. (France) Product
Table 103. Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 104. Sanofi S.A. (France) Recent Development
Table 105. Symic Bio, Inc. (US) Company Details
Table 106. Symic Bio, Inc. (US) Business Overview
Table 107. Symic Bio, Inc. (US) Product
Table 108. Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 109. Symic Bio, Inc. (US) Recent Development
Table 110. TheraVasc Inc. (US) Business Overview
Table 111. TheraVasc Inc. (US) Product
Table 112. TheraVasc Inc. (US) Company Details
Table 113. TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 114. TheraVasc Inc. (US) Recent Development
Table 115. AnGes MG, Inc. (Japan) Company Details
Table 116. AnGes MG, Inc. (Japan) Business Overview
Table 117. AnGes MG, Inc. (Japan) Product
Table 118. AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 119. AnGes MG, Inc. (Japan) Recent Development
Table 120. Athersys, Inc. (US) Company Details
Table 121. Athersys, Inc. (US) Business Overview
Table 122. Athersys, Inc. (US) Product
Table 123. Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 124. Athersys, Inc. (US) Recent Development
Table 125. Betagenon AB (Sweden) Company Details
Table 126. Betagenon AB (Sweden) Business Overview
Table 127. Betagenon AB (Sweden) Product
Table 128. Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 129. Betagenon AB (Sweden) Recent Development
Table 130. miRagen Therapeutics, Inc. (US) Company Details
Table 131. miRagen Therapeutics, Inc. (US) Business Overview
Table 132. miRagen Therapeutics, Inc. (US) Product
Table 133. miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 134. miRagen Therapeutics, Inc. (US) Recent Development
Table 135. Multi Gene Vascular Systems Ltd (Israel) Company Details
Table 136. Multi Gene Vascular Systems Ltd (Israel) Business Overview
Table 137. Multi Gene Vascular Systems Ltd (Israel) Product
Table 138. Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 139. Multi Gene Vascular Systems Ltd (Israel) Recent Development
Table 140. ViroMed Co. Ltd. (Korea) Company Details
Table 141. ViroMed Co. Ltd. (Korea) Business Overview
Table 142. ViroMed Co. Ltd. (Korea) Product
Table 143. ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2015-2020) (Million US$)
Table 144. ViroMed Co. Ltd. (Korea) Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Anti-Platelet Drugs Features
Figure 3. Dual Antiplatelet Therapy Drugs Features
Figure 4. Others Features
Figure 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Peripheral Arterial Disease (PAD) Therapeutics Report Years Considered
Figure 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players in 2019
Figure 15. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2019
Figure 17. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

---